Assessing blood tests for lung transplant rejection

Trifecta-Lung cfDNA-MMDx Study: Comparing the Dd-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test

Observational University of Alberta · NCT05837663

This study is testing if new blood tests can help doctors better detect lung transplant rejection by comparing them to traditional biopsy methods.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Alberta Academic / other
Locations18 sites (Phoenix, Arizona and 17 other locations)
Trial IDNCT05837663 on ClinicalTrials.gov

What this trial studies

This observational study aims to explore the relationship between donor-derived cell-free DNA (dd-cfDNA) levels and HLA antibodies in lung transplant recipients. It seeks to evaluate the effectiveness of the Molecular Microscope® Diagnostic System (MMDx) in analyzing biopsy samples and blood tests to improve the accuracy of rejection assessments. By comparing traditional biopsy methods with new blood tests, the study hopes to enhance patient safety and diagnostic precision in lung transplantation. The research will involve multiple institutions to gather comprehensive data on lung transplant outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adult lung transplant recipients who can provide informed consent.

Not a fit: Patients who are unable to give informed consent, those with multiple organ transplants, cancer patients, and pregnant women may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate and less invasive methods for monitoring lung transplant rejection.

How similar studies have performed: Previous studies using similar approaches in kidney transplantation have shown promising results, indicating potential for success in lung transplantation as well.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

Adult, Older adult

Exclusion Criteria:

Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women

Where this trial is running

Phoenix, Arizona and 17 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Lung TransplantationDonor derived cfDNAGene expressionLung transplant biopsyBlood
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.